• Denali Therapeutics Inc DNLI.OQ reported a quarterly adjusted loss of 78 cents​​ per share for the quarter ended March 31, identical to the same quarter last year. The mean expectation of sixteen analysts for the quarter was for a loss of 69 cents per share. Wall Street expected results to range from -77 cents to -51 cents per share.

• Reported revenue was zero​; analysts expected $1.05 million.

• Denali Therapeutics Inc's reported EPS for the quarter was a loss of 78 cents​.

• The company reported a quarterly loss of $132.97 million.

• Denali Therapeutics Inc shares had risen by 17.6% this quarter and lost 21.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 17.1% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Denali Therapeutics Inc is $34.00

This summary was machine generated from LSEG data May 6 at 08:28 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)